产品
编 号：F745654
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1518996-49-0
产品详情
生物活性：
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).
体内研究：
Andecaliximab 改善肿瘤浸润 T 细胞内 T 细胞受体 (TCR) 的多样性。Andecaliximab (20 mg/kg；腹腔注射，单次) 在特发性肺纤维化的人源 NSG 小鼠模型中显示出抗纤维化功效。Animal Model:Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg, once a week for once
Result:Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations.
体外研究：
Andecaliximab 增加血清中 IL-7 的水平。Andecaliximab (50 μg/mL；24 h)减少 ABC 类细胞系的 SMAD2 磷酸化 (pSMAD2)。
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).
体内研究：
Andecaliximab 改善肿瘤浸润 T 细胞内 T 细胞受体 (TCR) 的多样性。Andecaliximab (20 mg/kg；腹腔注射，单次) 在特发性肺纤维化的人源 NSG 小鼠模型中显示出抗纤维化功效。Animal Model:Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg, once a week for once
Result:Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations.
体外研究：
Andecaliximab 增加血清中 IL-7 的水平。Andecaliximab (50 μg/mL；24 h)减少 ABC 类细胞系的 SMAD2 磷酸化 (pSMAD2)。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备